CALCRL and melanoma: Among the 32 tumour entities investigated, strong CALCRL expression was present in all types of thyroid carcinomas, as well as parathyroid adenomas, small-cell lung cancers, large cell neuroendocrine carcinomas of the lung, pancreatic neuroendocrine neoplasms, renal clear cell carcinomas, pheochromocytomas, lymphomas, and melanomas.